{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:06:03Z","timestamp":1768442763840,"version":"3.49.0"},"reference-count":61,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,5,21]],"date-time":"2012-05-21T00:00:00Z","timestamp":1337558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Disease Overview:<\/jats:italic> Mantle cell lymphoma (MCL) is a non\u2010Hodgkin lymphoma characterized by involvement of the lymph nodes, spleen, blood, and bone marrow with a short remission duration to standard therapies and a median overall survival of 4\u20135 years.<\/jats:p><jats:p><jats:italic>Diagnosis:<\/jats:italic> Diagnosis is based on lymph node, bone marrow, or tissue morphology of centrocytic lymphocytes, small cell type, or blastoid variant cells. A chromosomal translocation <jats:italic>t<\/jats:italic>(11:14) is the molecular hallmark of MCL, resulting in the overexpression of cyclin D1. Cyclin D1 is detected by immunohistochemistry in 98% of cases. The absence of SOX\u201011 or a low Ki\u201067 may correlate with a more indolent form of MCL. The differential diagnosis of MCL includes small lymphocytic lymphoma, marginal zone lymphoma, and follicular lymphoma.<\/jats:p><jats:p><jats:italic>Risk Stratification:<\/jats:italic> The mantle cell lymphoma international prognostic index (MIPI) is the prognostic model most often used and incorporates ECOG performance status, age, leukocyte count, and lactic dehydrogenase. A modification of the MIPI also adds the Ki\u201067 proliferative index if available. The median overall survival (OS) for the low\u2010risk group was not reached (5\u2010year OS of 60%). The median OS for the intermediate risk group was 51 and 29 months for the high\u2010risk group.<\/jats:p><jats:p><jats:italic>Risk\u2010Adapted Therapy:<\/jats:italic> For selected indolent, low MIPI MCL patients, initial observation may be appropriate therapy. For younger patients with intermediate or high risk MIPI MCL, aggressive therapy with a cytarabine containing regimen \u00b1 autologous stem cell transplantation should be considered. For older MCL patients with intermediate or high risk MIPI, combination chemotherapy with R\u2010CHOP, R\u2010Bendamustine, or a clinical trial should be considered. At the time of relapse, agents directed at activated pathways in MCL cells such as bortezomib (NFkB inhibitor), BTK inhibitors or CAL\u2010101 (B\u2010cell receptor inhibitors) or lenalidamide (antiangiogenesis) have clinical activity in MCL patients. Autologous or allogeneic stem cell transplantation can also be considered in young patients. Am. J. Hematol. 87:604\u2013609, 2012. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23176","type":"journal-article","created":{"date-parts":[[2012,5,21]],"date-time":"2012-05-21T12:41:35Z","timestamp":1337604095000},"page":"604-609","source":"Crossref","is-referenced-by-count":81,"title":["Mantle cell lymphoma: 2012 update on diagnosis, risk\u2010stratification, and clinical management"],"prefix":"10.1002","volume":"87","author":[{"given":"Julie M.","family":"Vose","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,5,21]]},"reference":[{"key":"e_1_2_2_2_2","first-page":"405","article-title":"Classification of non\u2010Hodgkin's lymphomas","volume":"2","author":"Gerard\u2010Marchant R","year":"1974","journal-title":"Lancet"},{"key":"e_1_2_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0308-2261(74)80005-6"},{"key":"e_1_2_2_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820401)49:7<1429::AID-CNCR2820490720>3.0.CO;2-5"},{"key":"e_1_2_2_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_2_6_2","volume-title":"WHO Classification of Tumors of the Hematopietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_2_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"e_1_2_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05716.x"},{"key":"e_1_2_2_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22715"},{"key":"e_1_2_2_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-179739"},{"key":"e_1_2_2_11_2","first-page":"329","article-title":"Mantle cell lymphoma: A retrospective study of 121 cases","volume":"34","author":"Samaha H","year":"1998","journal-title":"Leukemia"},{"key":"e_1_2_2_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11096"},{"key":"e_1_2_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2007.04.026"},{"key":"e_1_2_2_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.767"},{"key":"e_1_2_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00028-X"},{"key":"e_1_2_2_16_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3419"},{"key":"e_1_2_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402272"},{"key":"e_1_2_2_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2230"},{"key":"e_1_2_2_19_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2008.n.019"},{"key":"e_1_2_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm447"},{"key":"e_1_2_2_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_2_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_2_2_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-236570"},{"key":"e_1_2_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00028-X"},{"key":"e_1_2_2_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0410"},{"key":"e_1_2_2_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.6121"},{"key":"e_1_2_2_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/1096-8652(200007)64:3<190::AID-AJH9>3.0.CO;2-B"},{"key":"e_1_2_2_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.317"},{"key":"e_1_2_2_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.5.1288"},{"key":"e_1_2_2_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"e_1_2_2_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.546"},{"key":"e_1_2_2_32_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109097721"},{"key":"e_1_2_2_33_2","doi-asserted-by":"crossref","first-page":"439a","DOI":"10.1182\/blood.V118.21.439.439","article-title":"R\u2010CHOP versus R\u2010FC followed by Maintenance with Rituximab versus interferon\u2010alfa: Outcome of the first randomized trial for elderly patients with mantle cell lymphoma","volume":"118","author":"Kluin\u2010Nelemans JC","year":"2011","journal-title":"Blood"},{"key":"e_1_2_2_34_2","doi-asserted-by":"crossref","first-page":"385a","DOI":"10.1182\/blood.V110.11.385.385","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab in the first\u2010line treatment of patients with indolent and mantle cell lymphomas first interim results of a randomized phase III study of the Stil","volume":"110","author":"Rummel M","year":"2007","journal-title":"Blood"},{"key":"e_1_2_2_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.1142"},{"key":"e_1_2_2_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3883"},{"key":"e_1_2_2_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"e_1_2_2_38_2","doi-asserted-by":"crossref","first-page":"387a","DOI":"10.1182\/blood.V110.11.387.387","article-title":"A multi center trial of HyperCVAD + Rituxan in patients with newly diagnosed mantle cell lymphoma","volume":"110","author":"Epner E","year":"2007","journal-title":"Blood"},{"key":"e_1_2_2_39_2","doi-asserted-by":"crossref","first-page":"424a","DOI":"10.1200\/jco.2006.24.18_suppl.7511","article-title":"Mantle cell lymphoma (MCL): Induction therapy with HyperCVAD\/high dose methotrexate and cytarabine (MC) +\/\u2010 rituximab improves results of autologous stem cell transplant in first remission","volume":"24","author":"Vose J","year":"2006","journal-title":"J Clin Oncol"},{"key":"e_1_2_2_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.7055"},{"key":"e_1_2_2_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025"},{"key":"e_1_2_2_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl127"},{"key":"e_1_2_2_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-369629"},{"key":"e_1_2_2_44_2","doi-asserted-by":"crossref","first-page":"8034a","DOI":"10.1200\/jco.2007.25.18_suppl.8034","article-title":"Bendamustine and rituximab (BR) are effective in the treatment of relapsed or refractory indolent and mantle\u2010cell lymphomas: Long term follow up of a phase II study","volume":"25","author":"Rummel M","year":"2007","journal-title":"J Clin Oncol"},{"key":"e_1_2_2_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"e_1_2_2_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_2_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn656"},{"key":"e_1_2_2_48_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-314708"},{"key":"e_1_2_2_49_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-189977"},{"key":"e_1_2_2_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23580"},{"key":"e_1_2_2_51_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7977"},{"key":"e_1_2_2_52_2","doi-asserted-by":"crossref","first-page":"121a","DOI":"10.1182\/blood.V110.11.121.121","article-title":"A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed aggressive non\u2010Hodgkin's lymphoma","volume":"110","author":"Reeder C","year":"2007","journal-title":"Blood"},{"key":"e_1_2_2_53_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V112.11.262.262"},{"key":"e_1_2_2_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07626.x"},{"key":"e_1_2_2_55_2","first-page":"109a","article-title":"Oral Lenalidamide plus 4 doses of Rituximab induced prolonged remissions in relapsed\/refractory mantle cell lymphoma: A completed phase I\/II clinical trial","volume":"22","author":"Wang M","year":"2011","journal-title":"Ann Oncol"},{"key":"e_1_2_2_56_2","doi-asserted-by":"crossref","first-page":"442a","DOI":"10.1182\/blood.V118.21.442.442","article-title":"The Bruton's tyrosine kinase inhibitor PCI\u201032765 is highly active as single\u2010agent therapy in previously\u2010treated mantle cell lymphoma (MCL): Preliminary results of a phase II trial","volume":"118","author":"Wang L","year":"2011","journal-title":"Blood"},{"key":"e_1_2_2_57_2","first-page":"350a","article-title":"Significant clinical activity of CAL\u2010101, an isoform selective inhibitor of phosphatidylinositol 3 kinase P110D, in patients with relapsed or refractory indolent and mantle cell lymphoma","volume":"22","author":"Kahl B","year":"2011","journal-title":"Ann Oncol"},{"key":"e_1_2_2_58_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.8545"},{"key":"e_1_2_2_59_2","doi-asserted-by":"crossref","first-page":"389a","DOI":"10.1182\/blood.V110.11.389.389","article-title":"Phase II study of R\u2010CHOP followed by 90Y\u2010Ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative Oncology Group Study E1499","volume":"110","author":"Smith MR","year":"2007","journal-title":"Blood"},{"key":"e_1_2_2_60_2","first-page":"18a","article-title":"Outcome of patients with mantle cell lymphoma undergoing autologous versus reduced\u2010intensity allogeneic transplantation","volume":"22","author":"Fenske TS","year":"2011","journal-title":"Ann Oncol"},{"key":"e_1_2_2_61_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184200"},{"key":"e_1_2_2_62_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2275"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23176","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T15:21:10Z","timestamp":1700580070000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,21]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1002\/ajh.23176"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23176","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,21]]}}}